SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a director's significant insider stock purchase and positive fiscal second-quarter results that exceeded earnings expectations, including record operating income and a raised EBITDA outlook. Community sentiment is largely bullish, though some investors express frustration over a lack of corporate communication regarding long-term strategy and potential acquisitions.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The community is debating the effectiveness of the Treasury's bond buyback program and rising long-term yields, with many traders expressing skepticism about the administration's ability to control the bond market. Conflicting viewpoints dominate the discussion, as some traders anticipate a short-term rally in bonds driven by upcoming buyback operations, while others remain bearish, citing persistent inflation, heavy national debt, and the potential for further interest rate hikes.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares are experiencing a significant sell-off following the release of quarterly financial results that featured a revenue guidance forecast falling below analyst expectations. Traders are debating whether the decline is an overreaction to the slight guidance miss and management changes, or if it represents a fundamental repricing of the stock.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The conversation is fragmented, with traders debating whether algorithmic market management is artificially propping up prices against a backdrop of rising bond yields and energy costs. Participants are divided between those expecting a significant correction due to macro headwinds and those betting on a continued 'V-shaped' recovery driven by AI-related momentum.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following market speculation regarding a potential $400 million U.S. Army contract for its LOCUST laser weapon system, though community sentiment remains split between optimism for future defense backlog growth and frustration over the stock's recent volatility and technical performance.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics is trending after reporting positive topline results from its VEGA-3 Phase 3 clinical trial, which met primary endpoints for its Phentolamine ophthalmic solution in treating presbyopia. While the community reaction includes optimism regarding the company's progress and upcoming regulatory filings, some traders remain skeptical, citing concerns over management performance and historical stock dilution.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is experiencing a sharp decline in price, primarily driven by broader market volatility and a sector-wide rotation away from high-beta AI infrastructure stocks. While investors continue to express confidence in the company's long-term role as a provider of critical power and cooling for data centers, the recent pullback is being fueled by general market apprehension regarding AI sector valuations and high-volatility trading patterns.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath shares experienced significant volatility following a second-quarter report that featured a revenue beat and raised guidance but was met with skepticism due to slowing annualized recurring revenue growth. Traders are divided between those who view the sell-off as an overreaction and a buying opportunity for a debt-free, profitable company, and those who remain concerned about intensifying competition and a lack of clear growth acceleration.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are attracting attention following the rollout of Muse, a new AI agent capable of performing autonomous tasks across various applications. Traders are divided on the product's long-term monetization potential and impact on the stock versus the company's significant ongoing AI-related capital expenditures.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech shares are seeing significant volatility and a partial recovery following a steep decline driven by a reported advertising algorithm issue that forced the company to lower its near-term revenue guidance. Investors are currently debating whether the sell-off represents an overreaction due to the company's strong cash position and share buyback authorization, or if the lack of clear forward guidance indicates deeper, persistent challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Five Market Stories Heating Up Right Now

The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.read more...

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.read more...

Five High-Voltage Stories in Focus

The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup...

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.57% and +1.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Moderate Buy" from Analysts

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating...

Extremely Bullish Sentiment

Yes, hike is locked in

No, inflation data still matters more

Fed stays on hold anyway

Too early to tell

August nonfarm payrolls surged by 162,000, nearly triple the 53,000-56,000 consensus estimate and the strongest monthly gain since March, while unemployment held steady at 4.1%, adding fuel to the case for a Federal Reserve rate hike at its September meeting. Does this jobs report cement a September rate hike? Vote and explain your reasoning in the comments.

August nonfarm payrolls surged 162,000, nearly triple estimates, while unemployment held at 4.1%. Does this cement a September rate hike?

Stocktwits

Stocktwits Polls

Positive Phase 1/2 clinical trial data and FDA meeting alignment have ignited significant investor optimism.

Traders are actively monitoring the stock for potential volatility as aggressive short positions face pressure.

Enthusiastic retail participants are debating key resistance levels and potential long-term double-digit price targets.

Investors are highlighting strong clinical progress and long-term milestones as reasons to hold into the future.

Current Price	$5.63
Prev Close	$4.34
Open	$5.38
Dividend Yield	0.00%
50-Day Moving Average	$3.78
Beta	1.06
Avg. Volume	821,811.48
PE Ratio	-3.15

52-Week High	$5.81
52-Week Low	$1.32
Market Capitalization	$361.07M
EPS (Annual)	-$0.797
Price to Book	-27.62
Revenue Per Employee	$507,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRD Fundamentals